
The initial promise of zzso zzso as major therapeutic agents in human zzso cancer has not been zzso zzso of cells in solid tumors due to factors such as the nature of the vascular zzso and high pressure in the tumor are primarily responsible for the failure of zzso zzso Although new strategies employing zzso zzso and zzso designed to actively engage the immune system may prove zzso zzso tumor cells (at the stage of minimal residual disease) are likely to be the only suitable targets for zzso zzso The diagnostic approaches to identify and characterize these cells and their use for prognosis and monitoring zzso zzso is zzso 

